Xie Dong
Xie Dong — Chief Physician — Thoracic Surgery — Shanghai Pulmonary Hospital
Specialties
Ground-glass nodules, ground-glass opacities, GGN, GGO, differential diagnosis and minimally invasive treatment of pulmonary nodules and early lung cancer, single-port minimally invasive surgical treatment of pulmonary nodules (including solid nodules and subsolid nodules), difficult or complex thoracic surgery, second thoracic surgery, surgery for downstaged lung cancer after targeted therapy or immunotherapy, and proficiency in comprehensive lung cancer treatment (including targeted therapy, chemotherapy, immunotherapy), as well as tumor efficacy imaging evaluation. Skilled in surgical treatment of tracheal tumors, tracheal stenosis, tracheoesophageal fistula, large tumors of the chest cavity and chest wall, surgical treatment of thymic tumors (thymoma, recurrent thymoma, thymic carcinoma), mediastinal neurogenic tumors, and mediastinal teratomas, especially single-port thoracoscopic minimally invasive surgery for early thymoma. Lung transplantation: interstitial pneumonia, idiopathic pulmonary fibrosis, COPD (severe emphysema), pulmonary hypertension, pulmonary lymphangioleiomyomatosis, etc. Surgical treatment of pleural and chest wall diseases: chest wall tumors, pleural tumors, malignant pleural mesothelioma, etc.
Professional Experience
Deputy Administrative Director of the Thoracic Surgery Department at Shanghai Pulmonary Hospital, Chief Physician, Professor, PhD Supervisor, Postdoctoral Co-supervisor, member of IASLC (International Association for the Study of Lung Cancer), member of AME Academic Salon Committee, member of EACTS (European Association for Cardio-Thoracic Surgery), member of ESTS (European Society of Thoracic Surgeons), and member of STS (Society of Thoracic Surgeons). From 2013 to 2014, he studied at the Thoracic Surgery and Cancer Center of the Mayo Clinic in the United States. He performs over 1,500 surgeries annually. His main research areas include precision treatment of lung cancer based on clinical big data and artificial intelligence research related to lung cancer. As the first author or corresponding author, he has published over 80 SCI papers in journals such as JTO (2014), NC (2024, 2025), EJC (1 article), JTCVS (2 articles), EJCTS (9 articles), ATS (7 articles), Acta Pharmacol Sin, Acta Biomater, AFM, Small, Biomaterials (3 articles), and has delivered more than 10 presentations at international conferences. He is skilled in minimally invasive treatment of pulmonary ground-glass nodules, ground-glass shadows, GGN, GGO, lung nodules, and early-stage lung cancer, including single-port minimally invasive surgery for lung nodules (including solid and subsolid nodules). He is also proficient in the comprehensive treatment of lung cancer, thymic tumors (thymoma, thymic cyst, thymic carcinoma), and mediastinal tumors.
Professional Roles
Deputy Director of the Thoracic Surgery Rehabilitation Group of the Chinese Medical Promotion Association Enhanced Recovery Surgery Branch; Young Editorial Board Member of the Chinese Journal of Cardiothoracic Surgery; Youth Member of the Thoracic Surgery Branch of the Chinese Medical Promotion Association; Member of the Oncology Science Popularization Committee of the Medical Popularization Branch of the Chinese Medical Doctor Association; Standing Committee Member of the Lung Cancer Medical Education Committee of the Chinese Society of Medical Education; Member of the Shanghai Thoracic Surgery Branch of the Chinese Medical Doctor Association; Member of the CSCO Minimally Invasive Oncology Branch; Young Member of the Oncology Target Molecule Committee of the Shanghai Medical Association; Review Expert for journals such as JTO and JTD; Review Expert for the Annual Meeting of the American Association for Thoracic Surgery (STS).